XML 21 R11.htm IDEA: XBRL DOCUMENT

Major events during the nine months ended on May 31st, 2022	9 Months Ended
May 31, 2022
Major Events During Nine Months Ended On May 31st 2022
Major events during the nine months ended on May 31st, 2022	Note 5 – Major events during the nine months ended on May 31st, 2022 On February 4^th, 2022, the Company filed a Pre-14C Information Statement with the SEC. On February 15^th, 2022, the Company filed its Definitive 14-C Information Statement with the SEC. On February 17^th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement with an institutional investor. On February 18^th, 2022, the Company filed an S-1 Registration Statement with the SEC. On March 16^th, 2022, the Company received $240,000 loan, bearing a $40,000 interest. The entire unpaid Principal and interest, shall be due and payable at any time, or from time to time, from and after the earlier to occur (I) May 16, 2022, and (II) the initial date after the date hereof of a public or private offering of any securities. Any amount of principal or other amounts due under the Loan which is not paid when due (a “Payment Default”) shall result in a late charge being incurred and payable by the Maker in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum. On May 5^th, 2022, the Company announced a grant of Patent by the government of Hong Kong for it’s patent “System and Method for Hight Throughput Screening of Cancer Cells, as noted in our Press Release of that date. On May 10^th, 2022, the Company received final approval from Finra for a 1:120 reverse share split of the Company’s common stock, and name change to the current “CNBX Pharmaceuticals Inc.”, as noted in the 8K filed with the SEC that day. During the nine months ended May 31, 2022, the Company issued 20,027 shares of its common stock to an investor as a result of a convertible loan exercise in the sum of $225,228.

Major events during the nine months ended on May 31st, 2022

9 Months Ended

May 31, 2022

Major Events During Nine Months Ended On May 31st 2022

Major events during the nine months ended on May 31st, 2022

Note 5 – Major events during the nine months ended on May 31st, 2022

On February 4^th, 2022, the Company filed a Pre-14C Information Statement with the SEC.

On February 15^th, 2022, the Company filed its Definitive 14-C Information Statement with the SEC.

On February 17^th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement with an institutional investor.

On February 18^th, 2022, the Company filed an S-1 Registration Statement with the SEC.

On March 16^th, 2022, the Company received $240,000 loan, bearing a $40,000 interest.

The entire unpaid Principal and interest, shall be due and payable at any time, or from time to time, from and after the earlier to occur (I) May 16, 2022, and (II) the initial date after the date hereof of a public or private offering of any securities. Any amount of principal or other amounts due under the Loan which is not paid when due (a “Payment Default”) shall result in a late charge being incurred and payable by the Maker in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum.

On May 5^th, 2022, the Company announced a grant of Patent by the government of Hong Kong for it’s patent “System and Method for Hight Throughput Screening of Cancer Cells, as noted in our Press Release of that date.

On May 10^th, 2022, the Company received final approval from Finra for a 1:120 reverse share split of the Company’s common stock, and name change to the current “CNBX Pharmaceuticals Inc.”, as noted in the 8K filed with the SEC that day.

During the nine months ended May 31, 2022, the Company issued 20,027 shares of its common stock to an investor as a result of a convertible loan exercise in the sum of $225,228.